# Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

> **NCT00590577** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 652 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone palmitate 25 mg eq.
- **DRUG:** Paliperidone palmitate 150 mg eq.
- **DRUG:** Placebo
- **DRUG:** Paliperidone palmitate 100 mg eq.

## Key facts

- **NCT ID:** NCT00590577
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 652 (ACTUAL)
- **Last updated:** 2014-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00590577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00590577, "Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00590577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*